Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis

NCT01930890 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01930890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01930890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2013
Completion date
January 31, 2016
Enrollment
87 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis